Patients receiving treatment at Penn Medicine for cancer and blood disorders are right next door to the research centers where breakthroughs are being discovered every day. They are being treated by experts in hematology and medical oncology care and research who are working relentlessly to find new ways to prevent, detect and treat these diseases.
Research is at the core of what Penn Medicine is about, and it is a key component to finding new, effective treatments and prevention programs for cancer and hematologic disorders.
Clinical Trials for Patients
Today, more and more people are surviving cancer. It is because of clinical trials, many of which are conducted at here, that patients are benefiting from breakthrough therapies and treatments.
Penn's Abramson Cancer Center
, an NCI-designated comprehensive cancer center, oversees one of the largest clinical trial programs in the country, with more than 200 trials available at any one time.
Phase one and two clinical trials for cancer are part of the Developmental Therapeutics Program and the Clinical Investigations Research Program at the Abramson Cancer Center.
These new advances in cancer treatment are occurring every day, giving patients hope that even greater discoveries lie ahead. Through clinical trials:
- Diagnosing cancer has become more precise.
- Radiation and surgical techniques have advanced.
- Medications are more successful.
- Combinations of medical, surgical and radiation therapy are improving treatment effectiveness and enhancing outcomes.
- Strategies to address the late effects of cancer and its treatment are improving quality of life.
For Medical Professionals
Penn's Division of Hematology/Oncology in the Department of Medicine provides comprehensive hematology and medical oncology services, research and training. The division, with its colleagues in other medical specialties, is an integral part of Penn's Abramson Cancer Center, an NCI-designated cancer center. Division faculty is committed to the integration of leading edge research with highest quality and personalized care for our patients.
The division of hematology/oncology offers:
- Benign and malignant hematology
- Solid tumor oncology
- Autologous and Allogeneic stem cell transplants
- New treatments including molecularly targeted therapies, immunotherapy treatments, vaccine studies made available through innovative clinical trials
The division and the Abramson Cancer Center have made significant commitment and investment to enhance clinical research and patient comfort and support.
Penn Medicine provides a full breadth of clinical and support services to patients and family members through a variety of multidisciplinary clinical programs focused on specific types of cancer. Members of the division are all subspecialists focusing exclusively on a specific malignancy or blood disorder.
Basic, translational and clinical research in hematology and medical oncology is focused on understanding the biology and causes of cancer and blood disorders and on expediting the transfer of scientific advances from the laboratory bench to patients.
The focus of basic scientists in the division is in the following areas:
- Platelet biology
- Cancer biology
- Cancer immunobiology
- Cancer stem cells
- HIV/host blood center interactions
Clinical and translational research is a major focus for faculty in the division of hematology/oncology. Our research encompasses a highly integrated program involving physicians and scientists across the disease spectrum with particular focus in the areas of hematological malignancies, lung cancer, melanoma, head and neck cancer, GU and GI cancers.
Specialized resources include:
- Cancer Risk Evaluation Program
- Clinical Investigation/Phase I Program
- Comprehensive Hemophilia/Thrombosis Program
- Bone Marrow/Stem Cell Transplant Program
- Bone Marrow Failure Program
- Joint pediatric program between CHOP and HUP
Learn more about clinical trials.